Pharma
Commented by Stefan Feulner on June 6th, 2023 | 07:15 CEST
MediGene, BioNTech, BioNxt Solutions - New opportunities after the correction
Acquisitions by big pharma were increasingly expected in the biotechnology sector last year, but these largely failed to materialize. However, this trend could accelerate in the current year. On the one hand, pharmaceutical companies, such as the vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio. On the other hand, second-tier stocks are attractive targets due to the strong correction.
Read
Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST
BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns
Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.
Read
Commented by André Will-Laudien on May 31st, 2023 | 08:30 CEST
Biotech in turnaround mode! BioNTech, Defence Therapeutics, MorphoSys, Formycon - Take a close look at these shares!
Since the major pandemic wave in the biotech sector, most industry players have had to come to terms with normality again. Scolded investors quickly learned their lesson and are now looking warily at an industry that experienced its heyday between 2019 and 2021. Today, it is no longer the small announcements of hope that lead to significant price swings. After months of sell-offs, however, the sector is stabilizing for the first time, and some protagonists can report minor progress. When the sector trend weakens, selection is the trump card. Here are some suggestions.
Read
Commented by André Will-Laudien on May 16th, 2023 | 09:45 CEST
BioNTech, Bayer, BioNxt, Formycon - The next biotech wave is rolling in - select carefully now!
Even after Corona, the biotech sector remains an interesting investment sector because it is still important to keep an eye on the major widespread diseases. For many companies, this will probably mean a longer waiting game for investors. In addition to the promising research approaches and milestone plans, the cash reserves of these companies are also important. While having ample funding can lead to quick progress in the laboratory, it is crucial to have the necessary liquidity. In refinancing, however, things have become a little frostier since the rise in interest rates. Which companies should be put under the microscope?
Read
Commented by Stefan Feulner on May 16th, 2023 | 09:30 CEST
Morphosys, Defence Therapeutics, Evotec - A lot of movement in the biotech sector
The biotech sector is on the move. On the one hand, the industry has seen an increase in mergers and acquisitions in recent months. The pharmaceutical giant Pfizer, for example, recently took over Seagan for USD 43 billion. Other companies are likely to follow suit. In addition, many companies were able to break away from their lows of the past months and have further upside potential.
Read
Commented by Armin Schulz on May 8th, 2023 | 08:10 CEST
MorphoSys, BioNxt Solutions, Pfizer - After the pandemic is before the pandemic
No sooner has the Corona pandemic officially ended than the West Nile virus is knocking on Germany's door. According to Christian Drosten, it could spread in Germany via the mosquitoes that transmit the virus. Experts are already predicting the next pandemic, but when it will come remains uncertain. But other diseases such as cancer, malaria and antibiotic resistance are also on the rise. These diseases are exacerbated by food production and ageing populations, especially in Western industrialized nations. It is here where biotech and pharmaceutical companies are needed to alleviate people's suffering. We look at three such companies today.
Read
Commented by Juliane Zielonka on May 4th, 2023 | 08:50 CEST
Bayer AG, First Phosphate, Porsche - In the fast lane with the right stock mix
Can sustainability and profitability go hand in hand? When looking at First Phosphate, a company that recently went public, this is true. The Company has found its place in the niche of LFP batteries for the global energy transition. Porsche AG also knows that electromobility is winning the race. The eMacan is selling so well that CFO Meschke has set a target return of 19%. Is that what Bayer's new CEO, Bill Anderson, is thinking? The conglomerate of Consumer Health, Crop Science and Pharma has more potential than the market is currently pricing in.
Read
Commented by Fabian Lorenz on May 3rd, 2023 | 07:30 CEST
Starting signal for a share price rally? BioNTech, Bayer, and BioNxt Solutions ahead of important dates
Things can move fast in the biotech sector. The share price of Prometheus Biosciences shot up by a good 75% practically overnight. The reason: US pharmaceutical group Merck & Co wants to buy the Company specializing in treating immune diseases, thus strengthening its own product portfolio. Thanks to clever takeovers, Sartorius has also grown strongly in recent years, become a success story on the German stock market and risen to the DAX. The latest acquisition of the laboratory supplier is Polyplus. The French company develops DNA and RNA components for cell and gene therapies. Is BioNxt, also active in Germany, the next takeover candidate? In any case, the Company is taking big steps towards commercialization. Investors are also hoping for new impetus from Bayer and BioNTech. Both companies have important dates coming up. But analysts are skeptical.
Read
Commented by Armin Schulz on April 24th, 2023 | 08:30 CEST
BioNTech, Defence Therapeutics, Sartorius - Takeover fever in the biotech sector
In the past year, the NASDAQ Biotechnology Index took a severe beating until mid-June. In the meantime, an initial upward trend has developed, and the market is slowly heating up again because some biotech companies are still valued too cheaply. This is when the big players strike, such as Merck & Co, which recently bought Prometheus Biosciences for USD 10.8 billion. The buyer thus paid a premium of a whopping 75% on the previous day's closing price. The biotech start-up Tubulis has also agreed on a collaboration with Bristol-Myers Squibb that could bring more than USD 1 billion into the Munich-based company's coffers. Reason enough to take a look at three companies from the pharmaceutical and biotech sector.
Read
Commented by Stefan Feulner on April 24th, 2023 | 08:20 CEST
The second biotech series is catching up - BioNxt Solutions, Core One Labs, BB Biotech
The months-long correction hit the capital-intensive biotech sector particularly hard. Shares, mainly from the second tier, sometimes had to absorb markdowns of more than three-quarters of their market value and are trading far below their cash holdings. These upheavals are, of course, prompting the big players to acquire new developments at bargain prices and thus significantly increase the value of their portfolios.
Read